Literature DB >> 20926398

Clld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis.

Xiaobo Zhou1, Karl Münger.   

Abstract

Chronic lymphocytic leukemia deletion gene 7 (Clld7) is a candidate tumor suppressor on chromosome 13q14. Clld7 encodes an evolutionarily conserved protein that contains an RCC1 domain plus broad complex, tramtrack, bric-a-brac (BTB), and POZ domains. In this study, we investigated the biological functions of Clld7 protein in inducible osteosarcoma cell lines. Clld7 induction inhibited cell growth, decreased cell viability, and increased γ-H2AX staining under conditions of caspase inhibition, indicating activation of the DNA damage/repair pathway. Real-time PCR analysis in tumor cells and normal human epithelial cells revealed Clld7 target genes that regulate DNA repair responses. Furthermore, depletion of Clld7 in normal human epithelial cells conferred resistance to apoptosis triggered by DNA damage. Taken together, the biological actions of Clld7 are consistent with those of a tumor suppressor.
Copyright © 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926398      PMCID: PMC2982930          DOI: 10.1158/0008-5472.CAN-10-1960

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia.

Authors:  H Mabuchi; H Fujii; G Calin; H Alder; M Negrini; L Rassenti; T J Kipps; F Bullrich; C M Croce
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

2.  Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia.

Authors:  Daniel Mertens; Stephan Wolf; Petra Schroeter; Claudia Schaffner; Hartmut Döhner; Stephan Stilgenbauer; Peter Lichter
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

3.  Identification and characterization of DPZF, a novel human BTB/POZ zinc finger protein sharing homology to BCL-6.

Authors:  W Zhang; J Mi; N Li; L Sui; T Wan; J Zhang; T Chen; X Cao
Journal:  Biochem Biophys Res Commun       Date:  2001-04-13       Impact factor: 3.575

4.  Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer.

Authors:  J T Dong; J C Boyd; H F Frierson
Journal:  Prostate       Date:  2001-11-01       Impact factor: 4.104

5.  Identification of novel regions of allelic loss from a genomewide scan of esophageal squamous-cell carcinoma in a high-risk Chinese population.

Authors:  N Hu; M J Roth; M Polymeropolous; Z Z Tang; M R Emmert-Buck; Q H Wang; A M Goldstein; S S Feng; S M Dawsey; T Ding; Z P Zhuang; X Y Han; T Ried; C Giffen; P R Taylor
Journal:  Genes Chromosomes Cancer       Date:  2000-03       Impact factor: 5.006

6.  Genetic alterations detected on chromosomes 13 and 14 in Chinese non-small cell lung carcinomas.

Authors:  Fung Mei Kwong; Po Shan Wong; Maria Li Lung
Journal:  Cancer Lett       Date:  2003-03-31       Impact factor: 8.679

7.  Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion.

Authors:  Alain Latil; Laurent Chêne; Philippe Mangin; Georges Fournier; Philippe Berthon; Olivier Cussenot
Journal:  Prostate       Date:  2003-09-15       Impact factor: 4.104

8.  BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3.

Authors:  Lai Xu; Yue Wei; Jerome Reboul; Philippe Vaglio; Tae-Ho Shin; Marc Vidal; Stephen J Elledge; J Wade Harper
Journal:  Nature       Date:  2003-09-03       Impact factor: 49.962

9.  The BTB protein MEL-26 is a substrate-specific adaptor of the CUL-3 ubiquitin-ligase.

Authors:  Lionel Pintard; John H Willis; Andrew Willems; Jacque-Lynne F Johnson; Martin Srayko; Thimo Kurz; Sarah Glaser; Paul E Mains; Mike Tyers; Bruce Bowerman; Matthias Peter
Journal:  Nature       Date:  2003-09-03       Impact factor: 49.962

10.  The ubiquitin conjugating enzyme, UbcM2, engages in novel interactions with components of cullin-3 based E3 ligases.

Authors:  Kendra S Plafker; Jeffrey D Singer; Scott M Plafker
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

View more
  9 in total

1.  Identification of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP.

Authors:  Xiaobo Zhou; Rebecca M Baron; Megan Hardin; Michael H Cho; Jan Zielinski; Iwona Hawrylkiewicz; Pawel Sliwinski; Craig P Hersh; John D Mancini; Ke Lu; Derek Thibault; Amy L Donahue; Barbara J Klanderman; Bernard Rosner; Benjamin A Raby; Quan Lu; Adriana M Geldart; Matthew D Layne; Mark A Perrella; Scott T Weiss; Augustine M K Choi; Edwin K Silverman
Journal:  Hum Mol Genet       Date:  2011-12-02       Impact factor: 6.150

2.  Genome-wide interaction study identifies RCBTB1 as a modifier for smoking effect on carotid intima-media thickness.

Authors:  Liyong Wang; Tatjana Rundek; Ashley Beecham; Barry Hudson; Susan H Blanton; Hongyu Zhao; Ralph L Sacco; Chuanhui Dong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-11-07       Impact factor: 8.311

3.  A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma.

Authors:  Amitabh Sharma; Jörg Menche; C Chris Huang; Tatiana Ort; Xiaobo Zhou; Maksim Kitsak; Nidhi Sahni; Derek Thibault; Linh Voung; Feng Guo; Susan Dina Ghiassian; Natali Gulbahce; Frédéric Baribaud; Joel Tocker; Radu Dobrin; Elliot Barnathan; Hao Liu; Reynold A Panettieri; Kelan G Tantisira; Weiliang Qiu; Benjamin A Raby; Edwin K Silverman; Marc Vidal; Scott T Weiss; Albert-László Barabási
Journal:  Hum Mol Genet       Date:  2015-01-12       Impact factor: 6.150

4.  Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.

Authors:  O Bucur; A L Stancu; R Khosravi-Far; A Almasan
Journal:  Cell Death Dis       Date:  2012-02-02       Impact factor: 8.469

5.  Novel RCBTB1 variants causing later-onset non-syndromic retinal dystrophy with macular chorioretinal atrophy.

Authors:  Andrew J Catomeris; Brian G Ballios; Riccardo Sangermano; Naomi E Wagner; Jason I Comander; Eric A Pierce; Emily M Place; Kinga M Bujakowska; Rachel M Huckfeldt
Journal:  Ophthalmic Genet       Date:  2022-01-20       Impact factor: 1.274

6.  Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.

Authors:  Frauke Coppieters; Giulia Ascari; Katharina Dannhausen; Konstantinos Nikopoulos; Frank Peelman; Marcus Karlstetter; Mingchu Xu; Cécile Brachet; Isabelle Meunier; Miltiadis K Tsilimbaris; Chrysanthi Tsika; Styliani V Blazaki; Sarah Vergult; Pietro Farinelli; Thalia Van Laethem; Miriam Bauwens; Marieke De Bruyne; Rui Chen; Thomas Langmann; Ruifang Sui; Françoise Meire; Carlo Rivolta; Christian P Hamel; Bart P Leroy; Elfride De Baere
Journal:  Am J Hum Genet       Date:  2016-08-04       Impact factor: 11.025

7.  In vitro antitumor activity of Latcripin-15 regulator of chromosome condensation 1 domain protein.

Authors:  Li Tian; Xiaoli Wang; Xingyun Li; Ben Liu; Wei Zhang; Jing Cao; Anhong Ning; Min Huang; Mintao Zhong
Journal:  Oncol Lett       Date:  2016-09-08       Impact factor: 2.967

8.  Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival.

Authors:  D H Lee; S Amanat; C Goff; L M Weiss; J W Said; N B Doan; A Sato-Otsubo; S Ogawa; C Forscher; H P Koeffler
Journal:  Oncogenesis       Date:  2013-05-20       Impact factor: 7.485

9.  RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas.

Authors:  Olivier Mauduit; Céline Brulard; Tom Lesluyes; Vanessa Delcroix; Gaëlle Pérot; Nina Choublier; Mickael Michaud; Jessica Baud; Pauline Lagarde; Alain Aurias; Jean-Michel Coindre; Lydia Lartigue; Jean-Yves Blay; Frédéric Chibon
Journal:  Cancers (Basel)       Date:  2019-01-11       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.